Clinical Trials Browser

OTHER × abiraterone × Genitourinary × Clear all

NCT05751941 2026-03-16

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT06173362 2026-03-13

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT04748042 2026-03-06

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02772588 2026-01-27

AASUR in High Risk Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT03556904 2026-01-15

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Phase 2 Completed

14 enrolled 16 charts

Prostatic Neoplasms

NCT02125617 2026-01-14

uPARCRPC

Prostatic Neoplasms

NCT06384222 2025-12-30

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

Phase 2 Recruiting

Prostatic Neoplasms

NCT06378866 2025-12-26

DIVINE

Phase 2 Recruiting

Prostatic Neoplasms

NCT07299292 2025-12-23

Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)

Phase 2 Recruiting

Disease, Prostatic Neoplasms

NCT04175431 2025-12-18

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

Phase 2 Recruiting

Prostate Adenocarcinoma

NCT03511196 2025-12-04

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

Phase EARLY_PHASE1 Active not recruiting

Prostatic Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT01961843 2025-11-25

Abiraterone Acetate for Castrate Resistant Prostate Cancer

Phase NA Completed

Prostatic Neoplasms

NCT06060587 2025-10-22

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

Phase 2 Withdrawn

Prostatic Neoplasms

NCT05733351 2025-09-15

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms

NCT07154914 2025-09-04

A Novel Insight Into CRPC Progression and Immune: Evidence From Single-cell Spatial Transcriptome Multi-omics

Not yet recruiting

Metastatic Hormone-Sensitive Prostate Cance

NCT01848067 2025-05-04

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Phase 1/2 Completed

9 enrolled 9 charts

Prostatic Neoplasms

NCT04262154 2025-04-27

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03903835 2025-04-09

ProBio

Phase 3 Recruiting

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06832774 2025-02-18

Exploration of Treatment Effect of Novel Hormone Therapy Combined with Local Treatment Based on PSMA PET/CT Evaluation in MHSCP Patients

Phase 2 Not yet recruiting

Prostate Cancer Metastatic Disease

NCT05612880 2025-01-09

Physical Function During ARSI Treatment

Advanced Prostate Carcinoma

NCT02366494 2024-11-25

Micro RNAs to Predict Response to Androgen Deprivation Therapy

Prostatic Neoplasms

NCT04207255 2024-09-25

Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

Phase 2 Completed

69 enrolled 13 charts

Prostatic Neoplasms

NCT03770455 2024-07-09

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Phase 2 Terminated

8 enrolled 7 charts

Metastatic Castration-resistant Prostate Cancer

NCT03141671 2024-05-14

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03934840 2024-02-28

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05707468 2024-02-20

Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer

Phase NA Not yet recruiting

Oligometastatic Prostate Carcinoma

NCT06198387 2024-01-10

Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer

Phase NA Not yet recruiting

Oligo-metastatic Prostate Carcinoma

NCT06134271 2023-11-18

RASTOM

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT01949337 2023-09-28

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Phase 3 Unknown

1,311 enrolled 12 charts

Prostatic Neoplasms

NCT05705700 2023-02-27

Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)

Phase 2 Withdrawn

Prostatic Neoplasms

NCT02789878 2022-09-15

Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT01780220 2022-05-19

CARLHA

Phase 1/2 Completed

Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy

NCT05188911 2022-01-12

Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial

Neoplasm Metastasis, Prostatic Neoplasms

NCT01574937 2021-08-06

XL-184+Abiraterone in Post-Chemo CRPC

Phase 1 Completed

Prostatic Neoplasms

NCT02867020 2021-07-07

Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels

Phase 2 Completed

Prostatic Neoplasms

NCT04839055 2021-04-09

CoA-CRPC

Phase 1/2 Unknown

Castration-resistant Prostate Cancer

NCT03418324 2020-12-30

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

Phase 2 Completed

11 enrolled 17 charts

Prostatic Neoplasms

NCT02883166 2020-12-07

SNACK

Phase 1 Completed

Prostatic Neoplasms

NCT03173859 2020-11-18

AERA

Phase 2 Withdrawn

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT02036060 2020-11-16

ABIDO

Phase 2 Completed

Prostatic Neoplasms

NCT03644303 2019-11-14

TRAP

Phase NA Unknown

Neoplasm Metastasis, Prostatic Neoplasms

NCT02758132 2019-11-08

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

Phase 2 Terminated

1 enrolled 7 charts

Prostatic Neoplasms

NCT01677897 2019-03-05

MetAb-Pro

Phase 2 Completed

Prostatic Neoplasms

NCT01741753 2019-02-05

BKM120+Abiraterone Acetate for Metastatic CRPC

Phase 1 Terminated

Neoplasm Metastasis, Prostatic Neoplasms

NCT02254785 2017-12-06

Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

Phase 2 Unknown

Prostatic Neoplasms, Castration-Resistant

NCT01828476 2017-05-04

Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

Phase 2 Terminated

13 enrolled 5 charts

Prostatic Neoplasms